Health and Neurodevelopmental Outcomes at 2 Years of Extremely Preterm Infants Enrolled in the International PLUSS Trial of Intratracheal Budesonide

Brett J. Manley, The University of Melbourne, Kensington, Victoria, Australia; C. Omar F. Kamlin, University of Melbourne, London, England, United Kingdom; Peter G. Davis, University of Melbourne, Melbourne, Victoria, Australia; Kate L. Francis, Murdoch children's research institute, Melbourne, Victoria, Australia; Renae Allen, MCRI, Parkvile, Victoria, Australia; Katinka P. Bach, Starship Children's Hospital, Auckland, Auckland, New Zealand; Risha Bhatia, The Royal Women's Hospital, Melbourne, Australia, Melbourne, Victoria, Australia; Pita Birch, Mater Health, South Brisbane, Queensland, Australia; Jennifer A. Dawson, The Royal Women's Hospital, Melbourne, Victoria, Australia; Koert de Waal, John Hunter Children's Hospital, Newcastle, New South Wales, Australia; Callum Gately, University of Otago, Wellington, Wellington, New Zealand; Gayatri Jape, King Edward Memorial Hospital, Perth, Western Australia, Australia; Brenda Law, University of Alberta Faculty of Medicine and Dentistry, Edmonton, AB, Canada; Steven Resnick, King Edward Memorial Hospital, Perth, Western Australia, Australia; Georg Schmolzer, University of Alberta Faculty of Medicine and Dentistry, Edmonton, AB, Canada; Lex W. Doyle, Prof. Lex Doyle, Parkville, Victoria, Australia; Christopher JD. McKinlay, University of Auckland, Auckland, Auckland, New Zealand; Jeanie Cheong, Murdoch Children's Research Institute, Melbourne, Victoria, Australia